LGALS1 and neoplasm: Final tumor volumes in DOX-treated versus untreated mice for HepG2-M-derived tumors were reduced 6.4-fold, whereas the response to treatment for HepG2-GAL1-derived tumors was significantly lower (2.4-folds) (Fig. 2C).